These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15809202)

  • 1. Improvement of potential therapeutic value of tumor necrosis-alpha (TNF-alpha) by charge modulation in the tip region.
    Fonda I; Pernus M; Gaberc-Porekar V; Kenig M; Stalc A; Meager A; Menart V
    Eur Cytokine Netw; 2005; 16(1):17-26. PubMed ID: 15809202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
    Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
    Rathjen DA; Ferrante A; Aston R
    Immunology; 1993 Oct; 80(2):293-9. PubMed ID: 8262557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of human tumor necrosis factor-alpha.
    Shin HC; Cho KH
    Biotechnol Lett; 2005 Jan; 27(2):107-12. PubMed ID: 15703873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan.
    Menart V; Fonda I; Kenig M; Porekar VG
    Ann N Y Acad Sci; 2002 Nov; 973():194-206. PubMed ID: 12485860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis.
    Berleth ES; Nadadur S; Henn AD; Eppolito C; Shiojiri S; Gurtoo HL; Ehrke MJ; Mihich E
    Cancer Res; 1999 Nov; 59(21):5497-506. PubMed ID: 10554026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activity of mutants of human tumour necrosis factor-alpha.
    Kircheis R; Milleck J; Korobko VG; Shingarova LN; Behnke D; Schmidt HE
    Immunology; 1992 Jul; 76(3):433-8. PubMed ID: 1526652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New TNF-alpha analogues: a powerful but less toxic biological tool against tumours.
    Novaković S; Menart V; Gaberc-Porekar V; Stalc A; Sersa G; Cemazar M; Jezersek B
    Cytokine; 1997 Aug; 9(8):597-604. PubMed ID: 9245488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
    Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
    Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
    Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
    Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a solid-phase random peptide library to identify inhibitors of TNF-alpha mediated cytotoxicity in vitro.
    Chirinos-Rojas CL; Steward MW; Partidos CD
    Cytokine; 1997 Apr; 9(4):226-32. PubMed ID: 9112330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
    Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human scFv fragment against TNF-alpha from de novo design method.
    Chang H; Qin W; Li Y; Zhang J; Lin Z; Lv M; Sun Y; Feng J; Shen B
    Mol Immunol; 2007 Jul; 44(15):3789-96. PubMed ID: 17485112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A soluble 17 kDa tumour necrosis factor (TNF) mutein, TNF-SAM2, with membrane-bound TNF-like biological characteristics.
    Yoshida A; Kohchi C; Inagawa H; Nishizawa T; Hori H; Soma G
    Anticancer Res; 2006; 26(6A):4003-7. PubMed ID: 17195449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Participation of ICAM-1 in the cytotoxicity of TM-TNF-alpha mediated by TNF receptor I].
    Zheng F; Shi WF; Feng W; Jiang XD; Xu Y; Fan F; Li ZY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):42-4. PubMed ID: 15182619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the site on a TNF-alpha molecule which affects type II TNF receptor binding in human cells.
    Ikegami H; Arai N; Moriyasu J; Taniguchi M; Tsusaki K; Honji N; Kohno K; Ando S; Kurimoto M
    Lymphokine Cytokine Res; 1993 Jun; 12(3):173-80. PubMed ID: 7688581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between novel tumor necrosis factor-alpha mutants and receptors on tumor and normal cells.
    Nakamura S; Masegi T; Fukuoka M; Kitai K; Kato A; Ichikawa Y; Watanabe N; Niitsu Y
    Agric Biol Chem; 1991 Jan; 55(1):53-7. PubMed ID: 1369315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.